UNITED STATES

                       SECURITIES AND EXCHANGE COMMISSION

                             WASHINGTON, D.C. 20549

                                   Form 10-QSB

             QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(D) OF THE
                        SECURITIES EXCHANGE ACTS OF 1934

                  For the quarterly period ended June 30, 2003

                         Commission File Number 0-16286

                               MEDPLUS CORPORATION
             (Exact name of registrant as specified in its charter)

               Delaware                                   95-4082020
     (State or other jurisdiction of                  (I.R.S. Employer
     Incorporation  or  Organization)              Identification  Number)

                           54 BROAD STREET, SUITE 200B
                               RED BANK, NJ  07701
                    (Address of principal executive offices)

                                 (732) 212-1133
              (Registrant's telephone number, including area code)

                                       N/A
              (Former name, former address and former fiscal year,
                          If changed since last report)

Indicate by check mark whether the registrant (1) has filed all reports required
to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during
the  preceding  12  months  (or  for such shorter period that the registrant was
required  to  file  such  reports),  and  (2)  has  been  subject to such filing
requirements  for  the  past  90  days.  Yes [X]   No [  ]

As  of August 12, there were 39,447,178 shares of the registrant's Common Stock,
par  value  $.001  per  share,  outstanding.

FORWARD  LOOKING  STATEMENTS

Some  of  the  information  presented  in  this  quarterly  report  constitutes
forward-looking  statements  within  the  meaning  of  the  private  Securities
Litigation  Reform  Act  of  1995.  Statements  that  are  not historical facts,
including  statements  about  management's expectations for fiscal year 2003 and
beyond,  are  forward  looking  statements  and  involve  various  risks  and
uncertainties.  Although the Company believes that its expectations are based on
reasonable  assumptions  within  the  bounds  of  its knowledge, there can be no
assurance  that  actual  results  will  not differ materially from the Company's
expectations.  Factors  that could cause the actual results to differ materially
from  expectations are discussed in the Company's Annual Report on Form 10-K and
in  other  filings  with  the  Securities  and  Exchange  Commission.


<PAGE>
<TABLE>
<CAPTION>
                               MEDPLUS CORPORATION

                              REPORT ON FORM 10-QSB

                                TABLE OF CONTENTS



PART I                                                            PAGE NUMBER
------                                                            -----------
<S>                                                                  <C>
ITEM 1. - CONDENSED CONSOLIDATED FINANCIAL STATEMENTS


    Balance Sheet as of June 30, 2003 (Unaudited). . . . . . . . . .   3

    Statements of Operations for the Three Months ended
    June 30, 2003 and 2002 with Cumulative Totals Since
    April 1, 2003 (Unaudited). . . . . . . . . . . . . . . . . . . .   4

    Statements of Cash Flows for the Three Months ended
    June 30, 2003 and 2002 with Cumulative Totals Since
    April 1, 2003 (Unaudited). . . . . . . . . . . . . . . . . . . .   5

    Notes to Condensed Consolidated Financial Statements . . . . . .   6

ITEM 2. - MANAGEMENT'S DISCUSSION AND ANALYSIS OF THE
             FINANCIAL CONDITION AND RESULTS OF
             OPERATIONS. . . . . . . . . . . . . . . . . . . . . . .  11

PART II
-------

             Other Information . . . . . . . . . . . . . . . . . . .  12

             Signature Page. . . . . . . . . . . . . . . . . . . . .  13
</TABLE>


<PAGE>
<TABLE>
<CAPTION>
              PART I - ITEM 1. MEDPLUS CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                                  BALANCE SHEET
                                  JUNE 30, 2003
                                  (UNAUDITED)


                                     ASSETS
<S>                                                           <C>
CURRENT ASSETS
Cash in bank                                                  $   4,459
                                                              ----------

TOTAL ASSETS                                                      4,459
                                                              ----------

                      LIABILITIES AND STOCKHOLDERS DEFICIT

CURRENT LIABILITIES
  Accrued expenses                                            $  96,500
                                                              ----------

        TOTAL CURRENT LIABILITIES                             $  96,500
                                                              ----------

SHAREHOLDERS' DEFICIT
Preferred stock - 2,000,000 shares authorized,
    par value $.001, 2,000,000 shares issued and outstanding      2,000
Common stock -
    authorized, 100,000,000 shares authorized,
    par value $.001, 47,611,008 issued and outstanding           47,611
Additional paid in capital                                       47,468
Deficit accumulated in the development stage                   (189,120)
                                                              ----------

    TOTAL STOCKHOLDERS' DEFICIT                                 (92,041)
                                                              ----------

TOTAL LIABILITIES AND STOCKHOLDERS DEFICIT                    $   4,459
                                                              ==========
</TABLE>


    The accompanying notes are an integral part of the condensed consolidated
                              financial statements.


<PAGE>
<TABLE>
<CAPTION>
                      MEDPLUS CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
                      STATEMENTS OF OPERATIONS (UNAUDITED)
                FOR THE THREE MONTHS ENDED JUNE 20, 2003 AND 2002
                   WITH CUMULATIVE TOTALS SINCE APRIL 1, 2003


                                                               CUMULATIVE
                                                              TOTALS SINCE
                                                              APRIL 1, 2003
                                     2003           2002      (SEE NOTE 1)
                                ---------------  -----------  -------------
<S>                             <C>              <C>          <C>
REVENUES                        $            -   $         -  $          -
                                ---------------  -----------  -------------

OPERATING EXPENSES
Compensation                            12,000             -        12,000
Professional fees                       21,500             -        21,500
Other                                   12,041             -        12,041
                                ---------------               -------------
      TOTAL OPERATING EXPENSES  $       45,541             -  $     45,541
                                ---------------               -------------

NET LOSS                        $      (45,541)  $         -  $    (45,541)
                                ---------------  -----------  -------------


BASIC AND DILUTED LOSS
   PER SHARE

Loss Per Share From Operations  $       (0.001)  $         -  $          -
                                ===============  ===========  =============

Weighted average number of
  common shares outstanding         37,447,178    22,669,093
</TABLE>


    The accompanying notes are an integral part of the condensed consolidated
                              financial statements.


<PAGE>
<TABLE>
<CAPTION>
                             MEDPLUS CORPORATION AND SUBSIDIARIES
                                 (A DEVELOPMENT STAGE COMPANY)
                             STATEMENTS OF CASH FLOWS (UNAUDITED)
                       FOR THE THREE MONTHS ENDED JUNE 20, 2003 AND 2002
                          WITH CUMULATIVE TOTALS SINCE APRIL 1, 2003


                                                                                   CUMULATIVE
                                                                                  TOTALS SINCE
                                                                                 APRIL 1, 2003
                                                          2003          2002     (SEE NOTE 1)
                                                     ---------------  ---------  -------------
<S>                                                  <C>              <C>        <C>

CASH FLOWS FROM OPERATING ACTIVITIES
  Net Loss                                           $      (45,541)  $       -  $    (45,541)
                                                     ---------------  ---------  -------------

ADJUSTMENTS TO RECONCILE NET LOSS TO NET CASH
   USED IN OPERATING ACTIVITIES:
CHANGES IN LIABILITIES:
  Accounts payable and accrued expenses                           -           -             -
      TOTAL ADJUSTMENTS                                           -           -             -
      NET CASH USED IN OPERATING ACTIVITIES                 (45,541)          -       (45,542)


CASH FLOWS FROM FINANCING ACTIVITIES
   Issuance of common stock                                  50,000           -        50,000
         NET CASH PROVIDED BY  FINANCING ACTIVITIES          50,000           -        50,000

NET INCREASE IN CASH AND CASH EQUIVALENTS                     4,459           -         4,459

CASH AND CASH EQUIVALENTS - BEGINNING OF PERIOD                   -           -             -

CASH AND CASH EQUIVALENTS - END OF PERIOD            $        4,459   $       -  $      4,459
                                                     ===============  =========  =============
</TABLE>

    The accompanying notes are an integral part of the condensed consolidated
                              financial statements.


<PAGE>
                      MEDPLUS CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                             JUNE 30, 2003 AND 2002
                                   (UNAUDITED)



NOTE  1-  ORGANIZATION
          ------------

          The Company was incorporated in the State of Delaware in December 1986
          as Vision Technology International. They changed their name in 1992 to
          Medplus  Corporation.  The  Company  had  operated  in the health care
          financing  industry. The Company ceased all operations in 1998 and has
          little  or  no  viable  operations  since  that  date.

          On  April  20,  2003,  the  Company's  Board  of Directors voted to be
          regulated  as a Business Development Company pursuant to Section 54 of
          the  Investment Company Act of 1940. The decision to become a Business
          Development Company was made primarily to better reflect the Company's
          anticipated  future business and developing relationships. The Company
          does  not  intend  to  focus  its investments in any one industry; but
          intends to carefully screen any and all candidates that appear to have
          superior  investment  opportunities.

          Accordingly,  the  Company  is now a Business Development Company that
          has  elected  to be regulated pursuant to Section 54 of the Investment
          Company  Act  of 1940. A Business Development Company is an investment
          company  designed  to assist eligible portfolio companies with capital
          formation.

          With  this  new  designation,  the Company has decided to offset their
          existing  additional  paid-in  capital  to  the  deficits  that  had
          accumulated  since  inception (December 1986). The net result was that
          the  deficits  accumulated  in  the  development stage was left with a
          balance  of  $143,579.

NOTE 2-   SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES
          ----------------------------------------------

          DEVELOPMENT  STAGE  COMPANY
          ---------------------------

          Medplus  Corporation  is  a  development  stage  company.  The Company
          devotes  substantially all of its efforts to seek, investigate and, if
          warranted,  invest  in  other  companies.

          USE  OF  ESTIMATES
          ------------------

          The  preparation of financial statements in conformity with accounting
          principles generally accepted in the United States of America requires
          management  to make estimates and assumptions that affect the reported
          amounts  of assets and liabilities and disclosure of contingent assets
          and  liabilities  at  the  date  of  the  financial statements and the
          reported amounts of revenues and expenses during the reporting period.
          Actual  results  could  differ  from  those  estimates.


<PAGE>
                      MEDPLUS CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
        NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (CONTINUED)
                             JUNE 30, 2003 AND 2002
                                  (UNAUDITED)



NOTE  2-  SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES
          ----------------------------------------------
          (CONTINUED)

          BASIS  OF  PRESENTATION
          -----------------------

          The accompanying condensed consolidated financial statements have been
          prepared  on a going concern basis, which contemplates the realization
          of  assets and the satisfaction of liabilities in the normal course of
          business.  The  Company  has  been  inactive since 1998. These factors
          indicate  that  the  Company  will  be  unable  to continue as a going
          concern.  The  condensed  consolidated  financial  statements  do  not
          include  any  adjustments  relating  to  the  recoverability  and
          classification  of  recorded  asset  amounts  or  the  amounts  and
          classification  of  liabilities  that  might  be  necessary should the
          Company  be  unable  to  continue  as  a  going concern. The Company's
          continuation  as  a  going  concern  is  dependent upon its ability to
          generate sufficient cash to meet its obligations on a timely basis, to
          obtain  financing  as  may  be  required,  and  ultimately  to  attain
          successful  operations.

          PRINCIPLES  OF  CONSOLIDATION
          -----------------------------

          The  condensed  consolidated financial statements include the accounts
          of  the  Company  and  its  wholly-owned  subsidiaries:  Patient  Plus
          Occupational  Health  Centers, Inc. and Lincoln Professional Services,
          Inc.  All intercompany accounts and transactions have been eliminated.
          This  is  the  last  report  that  will  contain  the  above mentioned
          subsidiaries  as  they  have  been  abandoned.

          CASH  AND  CASH  EQUIVALENTS
          ----------------------------

          The  Company  considers  all  highly liquid debt instruments and other
          short-term  investments  with  an  initial maturity of three months or
          less  to  be  cash  or  cash  equivalents.

          At  June  30,  2003,  the  Company maintained cash and cash equivalent
          balances  at one financial institution which is insured by the Federal
          Deposit Insurance Corporation, whose amounts do not exceed the insured
          limit  of  $100,000.


<PAGE>
                      MEDPLUS CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (CONTINUED)
                             JUNE 30, 2003 AND 2002
                                   (UNAUDITED)



NOTE  2-  SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES
          ----------------------------------------------
          (CONTINUED)

          INCOME  TAXES
          -------------

          Deferred  income  taxes  are  reported  using  the  liability  method.
          Deferred  tax  assets  are  recognized  for  deductible  temporary
          differences  and  deferred  tax liabilities are recognized for taxable
          temporary  differences.  Temporary  differences  are  the  differences
          between  the  reported amounts of assets and liabilities and their tax
          bases.  Deferred tax assets are reduced by a valuation allowance when,
          in  the  opinion  of  management, it is more likely than not that some
          portion  or  all  of  the  deferred  tax  assets will not be realized.
          Deferred  tax  assets  and liabilities are adjusted for the effects of
          changes  in  tax  laws  and  rates  on  the  date  of  enactment.

          FAIR  VALUE  OF  FINANCIAL  INSTRUMENTS
          ---------------------------------------

          The  carrying  amounts  reported  in  the  balance  sheet for cash and
          accrued  expenses  approximate  fair value because of the immediate or
          short-term  maturity  of  these  financial  statements.

          ADVERTISING  COSTS
          ------------------

          The  Company's  expenses  the  costs  associated  with  advertising as
          incurred.  There  were no advertising costs for the three months ended
          June  30,  2003  and  2002,  respectively.

          EARNINGS  (LOSS)  PER  SHARE  OF  COMMON  STOCK
          -----------------------------------------------

          Historical  net  income  (loss) per common share is computed using the
          weighted average number of common shares outstanding. Diluted earnings
          per  shares  (EPS)  includes  additional  dilution  from  common stock
          equivalents,  such as stock issuable pursuant to the exercise of stock
          options  and  warrants.  Common stock equivalents were not included in
          the  computation  of  diluted  earnings  per  share  when  the Company
          reported  a  loss  because  to do so would be antidilutive for periods
          presented.


<PAGE>
                      MEDPLUS CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (CONTINUED)
                             JUNE 30, 2003 AND 2002
                                   (UNAUDITED)



NOTE  2-  SUMMARY  OF  SIGNIFICANT  ACCOUNTING  POLICIES
          ----------------------------------------------
          (CONTINUED)

          EARNINGS  (LOSS)  PER  SHARE  OF  COMMON  STOCK  (CONTINUED)
          ------------------------------------------------------------

          The  following  is  a  reconciliation of the computation for basic and
          diluted  EPS:

<TABLE>
<CAPTION>
                                             JUNE 30,     JUNE 30.
                                               2003         2002
                                           ------------  -----------
<S>                                        <C>           <C>
          Net loss                         $   (45,541)  $         -

          Weighted-average common shares
          Outstanding (Basic)               39,447,178    22,669,093

          Weighted-average common stock
          Equivalents
            Stock options
            Warrants

          Weighted-average common shares
          Outstanding (Diluted)             39,447,178    22,669,093
</TABLE>


          Options  and  warrants outstanding to purchase stock were not included
          in  the  computation of diluted EPS for June 30, 2003 and 2002 because
          inclusion  would  have  been  antidilutive.  There  were no options or
          warrants  outstanding  at  June  30,  2003  and  2002,  respectively.

          RECLASSIFICATIONS
          -----------------

          Certain  reclassifications  have  been  made to prior year captions in
          order  to  conform  to  current  year  presentation.


<PAGE>
                      MEDPLUS CORPORATION AND SUBSIDIARIES
                          (A DEVELOPMENT STAGE COMPANY)
              NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
                                   (CONTINUED)
                             JUNE 30, 2003 AND 2002
                                   (UNAUDITED)



NOTE  3-  STOCKHOLDERS'  DEFICIT
          ----------------------

          The Company issued 2,531,780 shares of common stock to an investor for
          $50,000  on  June  25,  2003.  The  Company  issued  the  stock  after
          rescinding a convertible debenture issued to the investor in May 2003.

NOTE  4-  PROVISION  FOR  INCOME  TAXES
          -----------------------------

          The  Company  did  not  provide  for in come taxes in the three months
          ended  June 30, 2003 and 2002. Additionally, the Company established a
          valuation  allowance  equal  to  the  full  amount of the deferred tax
          assets  due  to  the  uncertainty  of the utilization of the operating
          losses  in  future  periods.

          At  June  30,  2003  and 2002, the deferred tax assets consists of the
          following:

<TABLE>
<CAPTION>
                                                      2003    2002
                                                    --------  -----
<S>                                                 <C>       <C>
          Deferred taxes due to net operating loss
          carryforwards                             $ 6,900   $   -

          Less:  Valuation allowance                 (6,900)      -
                                                    --------  -----

          Net deferred tax asset                    $     -   $   -
                                                    ========  =====
</TABLE>



NOTE  5-  SUBSEQUENT  EVENTS
          ------------------

          The  Company  on  July  29,  2003 voted to change its name to Atlantis
          Business  Development  Corp. In addition, the Board of Directors voted
          to increase the common stock authorized of the Company to 200,000,000.
          Finally,  the  Company  approved  a  1  for  10  reverse  stock split.


<PAGE>
ITEM  2.  MANAGEMENT'S  DISCUSSION  AND  ANALYSIS  OF
-----------------------------------------------------
FINANCIAL  CONDITION  AND  RESULTS  OF  OPERATIONS
--------------------------------------------------

LIQUIDITY  AND  CAPITAL  RESOURCES
----------------------------------

At  June  30,  2003  the  Company  had  working capital of ($92,041) compared to
working  capital  of  ($96,500) at March 31, 2003. The working capital increased
was  due  to  the  Company's  financing  activities as a result of the change in
control  and  business  direction  during  these  periods. The Company's current
liabilities  are  higher  than  its  assets  due  primarily  to the deferred tax
liability.

The  Company's  liquidity  position  is  severely  strained. Liquidity needs are
currently  being  met  from  short-term  borrowing  in  the  form of convertible
promissory  notes.  On April 20, 2003, the Company's Board of Directors voted to
be  regulated  as  a  Business Development Company pursuant to Section 54 of the
Investment  Company Act of 1940. The Company's ability to continue operations is
dependent  upon  this  business  direction  change  and  it's  ability  to raise
additional  equity  and/or  debt  financing.  This  and  other  factors  raise
substantial  doubt  as  to the Company's ability to continue as a going concern.
Although  the  Company  is  actively  engaged in activities with intent to raise
equity  and/or  debt  financing  in order to meet its long-term liquidity needs,
there  can  be  no  assurance  that  the  Company will be able to consummate the
transaction  and/or  raise  the  additional  financing  necessary for continuing
operations.

RESULTS  OF  OPERATIONS
-----------------------

There was zero revenue derived from the Company for the three month period ended
June 30, 2003. Similarly there was zero revenue for the three month period ended
June  30,  2002.

There was $45,541 Operational Expenses for operations for the three month period
ended  June  30,  2003  compared  to Zero operation expenses for the three month
period ended June 30, 2002. This increase in operational expense is attributable
to the company changing control and business direction thereby resuming business
operations  once  again

There  were  no  Sales and Marketing expenses for operations for the three month
period  ended  June  30,  2003.


<PAGE>
                                     PART II
                                OTHER INFORMATION

ITEM  1.  LEGAL  PROCEEDINGS
          ------------------

          None

ITEM  2.  CHANGES  IN  SECURITIES
          -----------------------

          None

ITEM  3.  DEFAULTS  UPON  SENIOR  SECURITIES
          ----------------------------------

          None

ITEM  4.  SUBMISSION  OF  MATTERS  TO  A  VOTE  OF  SECURITIES  HOLDERS
          -------------------------------------------------------------

At  the  Annual  Meeting  of shareholders held on July 29, 2003, pursuant to the
Notice  of  Annual  Meeting  of  Stockholders  dated July 1, 2003, the following
actions  were  taken:
     1.   The  Proposal  to  elect,  Brian Zucker, Tim DeHerrera, Leon Reingold,
          Leon  Golden  and  John  Leo  directors  to hold office until the 2004
          Annual  Meeting of Stockholders and until their successors are elected
          and  qualified  was  approved  as  follows:
               Brian Zucker, Tim DeHerrera, Leon Reingold, Leon Golden, John Leo
               -  (23,852,365  shares  in  favor,  2,890  shares against; and no
               shares  abstained).
     2.   The  proposal  to appoint Bagell, Josephs & Company LLP as independent
          auditors for the Company for the fiscal year ending March 31, 2003 was
          approved  (23,853,903  shares  in  favor:  551 shares against; and 801
          abstained).
     3.   The  proposal  to  effect  a 1 for 10 reverse stock split was approved
          (23,649,929  shares  in  favor:  204,808  shares  against;  and  518
          abstained).
     4.   The proposal to amend the bylaws to allow no less than 3, no more than
          9  directors  of the Company was approved (23,848,979 shares in favor:
          5,308  shares  against;  and  968  abstained).
     5.   The  proposal  to  change the fiscal year of the Company to a calendar
          year  ending  December  31was  approved  (23,743,903  shares in favor:
          110,968  shares  against;  and  384  abstained).
     6.   The  proposal to change the name of the company to reflect anticipated
          activities  as a business development corporation to Atlantis Business
          Development  Corporation  was  approved  ( 23,851,439 shares in favor:
          3,275  shares  against;  and  551  abstained).
     7.   The  proposal  to  amend the Company's Certificate of Incorporation to
          change  the  authorized  shares  to  200,000,000 shares was approved (
          23,650,7330  shares  in  favor:  203,957  shares  against;  and  565
          abstained).

No  other  matters were submitted to a vote of the Company's stockholders during
the  second  quarter  of  the  fiscal  year  covered  by this report through the
solicitation  of  proxies  or  otherwise.


ITEM  5.  OTHER  INFORMATION
          ------------------

OFFER  AND COMPRIMISE ACCEPTED - On August 7, 2001, the Internal Revenue Service
accepted  an offer of $ 94,500 to settle outstanding payroll tax liabilities and
release  liens  associated  with payroll taxes from 1996 through 1999. The offer
was due to be paid in January 2002. The accrued payroll taxes have been adjusted
in  these  financial statements to reflect this settlement. This remains unpaid.

ITEM  6.  EXHIBITS  AND  REPORTS  ON  FORM  8-K

          (a)  Exhibits
          99-1 Statement  under  oath  of  principal  executive  officer.


<PAGE>
          99-2 Statement  under  oath  of  principal  officer.


          (b)  Reports  on  Form  8-K
               None

Signatures
----------

Pursuant  to  the  requirements  of the Securities and Exchange Act of 1934, the
registrant  has  duly  caused  this  report  to  be  signed on its behalf by the
undersigned  thereunto  duly  authorized.

                                        MEDPLUS  CORPORATION


Date:  August  12, 2003                 By /s/ Brian  Zucker
                                        ----------------------
                                        Brian  Zucker
                                        President

Date:  August  12, 2003                 By /s/ Tim  DeHerrera
                                        ----------------------
                                        Tim  DeHerrera
                                        Treasurer


<PAGE>
                               MEDPLUS CORPORATION
               ---------------------------------------------------
               CERTIFICATION PURSUANT TO RULE 13A-14 AND 15D-14 OF
                     THE SECURITIES AND EXCHANGE ACT OF 1934

I  Brian  Zucker,  President,  certify  that:

(1)  I  have  reviewed this quarterly report on form 10-Q of Medplus Corporation
     (the "registrant");

(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of  a material fact or omit to sate a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(3)  Based  on  my  knowledge,  the  financial  statements  and  other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  registrant  as  of,  and for, the periods presented in this
     quarterly  report;

(4)  The  registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules 13a-14 and 15d-14) for the registrant and we have:

     a) Designed such disclosure controls and procedures to ensure that material
     information  relating  to  the  registrant,  including  its  consolidated
     subsidiaries,  is  made  known  to  us  by  others  within  those entities,
     particularly  during  the  period  in  which this quarterly report is being
     prepared;

     b)  Evaluated the effectiveness of the registrant's disclosure controls and
     procedures  as  of  a  date within 90 days prior to the filing date of this
     quarterly  report  (the  "Evaluation  Date");  and

     c)  Presented  in  this  quarterly  report  our  conclusions  about  the
     effectiveness  of  the  disclosure  controls  and  procedures  based on our
     evaluation  as  of  the  Evaluation  Date;

(5)  The  registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the registrant's auditors and the audit
     committee  of  registrant's  board  of directors (or persons performing the
     equivalent  function):

     a)  All  significant  deficiencies  in  the design or operation of internal
     controls  which  could adversely affect the registrant's ability to record,
     process,  summarize  and  report financial data and have identified for the
     registrant's  auditors  any  material  weaknesses in internal controls: and

     b)  Any  fraud,  whether or not material, that involves management or other
     employees  who  have  a  significant  role  in  the  registrant's  internal
     controls;  and

(6)  The  registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  factors  that  could significantly affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.



Date:  August  12, 2003            By /s/  Brian  Zucker
                                   ---------------------
                                   Brian  Zucker
                                   President


<PAGE>
                               MEDPLUS CORPORATION
               ---------------------------------------------------

               CERTIFICATION PURSUANT TO RULE 13A-14 AND 15D-14 OF
                     THE SECURITIES AND EXCHANGE ACT OF 1934

I,  Tim  DeHerrera,  Treasurer,  certify  that:

(1)  I  have  reviewed this quarterly report on form 10-Q of Medplus Corporation
     (the  "registrant");

(2)  Based  on  my  knowledge, this quarterly report does not contain any untrue
     statement  of  a material fact or omit to sate a material fact necessary to
     make  the  statements  made, in light of the circumstances under which such
     statements  were made, not misleading with respect to the period covered by
     this  quarterly  report;

(3)  Based  on  my  knowledge,  the  financial  statements  and  other financial
     information  included  in  this  quarterly  report,  fairly  present in all
     material  respects  the financial condition, results of operations and cash
     flows  of  the  registrant  as  of,  and for, the periods presented in this
     quarterly  report;

(4)  The  registrant's  other  certifying  officers  and  I  are responsible for
     establishing and maintaining disclosure controls and procedures (as defined
     in  Exchange  Act  Rules 13a-14 and 15d-14) for the registrant and we have:

     a) Designed such disclosure controls and procedures to ensure that material
     information  relating  to  the  registrant,  including  its  consolidated
     subsidiaries,  is  made  known  to  us  by  others  within  those entities,
     particularly  during  the  period  in  which this quarterly report is being
     prepared;

     b)  Evaluated the effectiveness of the registrant's disclosure controls and
     procedures  as  of  a  date within 90 days prior to the filing date of this
     quarterly  report  (the  "Evaluation  Date");  and

     c)  Presented  in  this  quarterly  report  our  conclusions  about  the
     effectiveness  of  the  disclosure  controls  and  procedures  based on our
     evaluation  as  of  the  Evaluation  Date;

(5)  The  registrant's  other certifying officers and I have disclosed, based on
     our  most  recent  evaluation,  to  the registrant's auditors and the audit
     committee  of  registrant's  board  of directors (or persons performing the
     equivalent  function):

     a)  all  significant  deficiencies  in  the design or operation of internal
     controls  which  could adversely affect the registrant's ability to record,
     process,  summarize  and  report financial data and have identified for the
     registrant's  auditors  any  material  weaknesses in internal controls: and

     b)  any  fraud,  whether or not material, that involves management or other
     employees  who  have  a  significant  role  in  the  registrant's  internal
     controls;  and

(6)  The  registrant's  other  certifying  officers and I have indicated in this
     quarterly  report whether or not there were significant changes in internal
     controls  or  in  other  factors  that  could significantly affect internal
     controls  subsequent  to  the date of our most recent evaluation, including
     any corrective actions with regard to significant deficiencies and material
     weaknesses.


Date:  August  12,  2003                By /s/  Tim  DeHerrera
                                        ----------------------
                                        Tim  DeHerrera
                                        President


<PAGE>

                            CERTIFICATION PURSUANT TO
                            -------------------------
18  U.S.C.  SECTION  1350,
AS  ADOPTED  PURSUANT  TO
SECTION  906  OF  THE  SARBANES-OXLEY  ACT  OF  2002

In  connection  with the Quarterly Report of Medplus Corporation (the "Company")
on  Form  10-Q  for the quarter ended June 30, 2003 as filed with the Securities
and  Exchange  Commission  on  the  date hereof  (the "Report"), I Brian Zucker,
Chief  Executive  Officer of the Company, certify, pursuant to 18 U.S.C. Section
1350,  as  adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, to
the  best  of  my  knowledge,  that:

     (1)  The  Report  fully  complies with the requirements of Section 13(a) or
          15(d)  of  the  Securities  Exchange  Act  of  1934,  as  amended; and

     (2)  The  information  contained  in  the  report  fairly  presents, in all
          material  respects,  the financial condition and results of operations
          of  the  Company.

By:  /s/  Brian  Zucker
     Brian  Zucker
     President
     August  12,  2003


                            CERTIFICATION PURSUANT TO
                            -------------------------
18  U.S.C.  SECTION  1350,
AS  ADOPTED  PURSUANT  TO
SECTION  906  OF  THE  SARBANES-OXLEY  ACT  OF  2002



In  connection  with the Quarterly Report of Medplus Corporation (the "Company")
on  Form  10-Q  for the quarter ended June 30, 2003 as filed with the Securities
and  Exchange  Commission  on  the date hereof  (the "Report"), I Tim DeHerrera,
Treasurer  of  the  Company,  certify,  pursuant  to  18 U.S.C. Section 1350, as
adopted  pursuant  to Section 906 of the Sarbanes-Oxley Act of 2002, to the best
of  my  knowledge,  that:

     (3)  The  Report  fully  complies with the requirements of Section 13(a) or
          15(d)  of  the  Securities  Exchange  Act  of  1934,  as  amended; and

     (4)  The  information  contained  in  the  report  fairly  presents, in all
          material  respects,  the financial condition and results of operations
          of  the  Company.



By:  /s/  Tim  DeHerrera
     Tim  DeHerrera
     Treasurer
     August  12,  2003


<PAGE>